Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 15, 2026

KeyBanc Trims Snowflake’s Target to $200 as AI-Native Rivals Circle: Is the Data Cloud King Under Threat?

View original at finance.yahoo.com
KeyBanc Trims Snowflake’s Target to $200 as AI-Native Rivals Circle: Is the Data Cloud King Under Threat?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • U.S. federal results for Q2 and full-year FY26 outlook weakened

    60% confidence

  • 20% of channel partners are seeing a reduction in software spend in favor of AI-native alternatives

    60% confidence

  • Component pricing pulled forward demand in server, storage, and networking

    60% confidence

  • The winners will be the platforms that combine trusted enterprise data, govern business metrics, secure execution and broad model choice and make all of it easily accessible. That's exactly what Snowflake was built to do.

    60% confidence

  • The 2026 budget outlook moderated to 3% from 5% last quarter for enterprise software

    60% confidence

  • Public cloud spending outlook slightly improved

    60% confidence

  • The overall meets/beats rate improved to 88% from 81% for Q1

    60% confidence

Data points we hold from this source

Snowflake Inc. · price target200 USD
Snowflake Inc. · customer growth40 percent
Snowflake Inc. · net new customers740 customers
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
KeyBanc Trims Snowflake’s Target to $200 as AI-Native Rivals Circle: Is the Data Cloud King Under Threat? — Source | Via News | ViaNews EU